ArticleThe Journal of biological chemistry2019
Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motor.bioRxiv : the preprint server for biology · 2026Article
- Multi-omics Insight into Cardiac Myofibril Remodeling in Post-Prandial Burmese Pythons.bioRxiv : the preprint server for biology · 2026Article
- A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Evolution of Systems Biology and Systems Medicine: From Mechanistic Models to Uncertainty Quantification.Annual review of biomedical engineering · 2025Review
- Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling.Frontiers in physiology · 2025Article
- Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy.The EMBO journal · 2024Review
- UNC-45 assisted myosin folding depends on a conserved FXNature communications · 2024Article
- Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism.The journal of physical chemistry. B · 2024Article
- Incomplete-penetrant hypertrophic cardiomyopathyProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients.Science advances · 2023Review
- Cryo-EM structure of the folded-back state of human β-cardiac myosin.bioRxiv : the preprint server for biology · 2023Article
- Virus-free transfection, transient expression, and purification of human cardiac myosin in mammalian muscle cells for biochemical and biophysical assays.Scientific reports · 2023Article
- Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.Scientific reports · 2022Article
- Insights into the Mechanism of the Cardiac Drug Omecamtiv Mecarbil─A Computational Study.The journal of physical chemistry. B · 2022Article
- Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy.International journal of molecular sciences · 2022Review
- Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies.Frontiers in physiology · 2022Review
- Multiscale simulations of left ventricular growth and remodeling.Biophysical reviews · 2021Review
- Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.Biophysical journal · 2021Article
- Complexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine.The Journal of general physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Carlos D VeraBioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309.
Chloe A JohnsonSchool of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom.
Jonathan WalklateSchool of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom.
Arjun AdhikariDepartment of Biochemistry, Stanford University School of Medicine, Stanford, California 94305.
Marina SvicevicFaculty of Science, University of Kagujevac, Serbia.
Srboljub M MijailovichDepartment of Biology, Illinois Institute of Technology, Chicago, Illinois 60616.
Ariana C CombsBioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309.ORCID 0000-0001-8327-5074
Stephen J LangerBioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309.
Kathleen M RuppelDepartment of Biochemistry, Stanford University School of Medicine, Stanford, California 94305.
James A SpudichDepartment of Biochemistry, Stanford University School of Medicine, Stanford, California 94305.
Michael A GeevesSchool of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom m.a.geeves@kent.ac.uk.ORCID 0000-0002-9364-8898
Leslie A LeinwandBioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309 leslie.leinwand@colorado.edu.ORCID 0000-0003-1470-4810
University of Colorado Boulder · USStanford University · USUniversity of Kent · GBIllinois Institute of Technology · USUniversity of Kragujevac · RS
Funding
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6MMYOSIN GENE DIVERSITY AND FUNCTIONR01GM029090 · NIGMS · YESHIVA UNIVERSITY · PI Leslie Anne Leinwand · 1985 to 2026
$12.3MMolecular Characterization of Cardiomyopathy Mutations in Human Cardiac MyosinR01HL117138 · NHLBI · UNIVERSITY OF COLORADO · PI LEINWAND, LESLIE ANNE, PERKINS, THOMAS TUPPER · 2013 to 2021
$4.2MFunctional analysis of novel MYH7 mutations with prevalence in early-onset patientsF31GM111058 · NIGMS · UNIVERSITY OF COLORADO · PI VERA, CARLOS D · 2016 to 2017
$71kNHLBI NIH HHS R01 HL117138NIDDK NIH HHS P30 DK048520NIGMS NIH HHS F31 GM111058NIGMS NIH HHS R01 GM029090
Abstract
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterized by left ventricular hypertrophy and cardiac hyper-contractility. Mutations in the β-cardiac myosin heavy chain gene (β-
Indexed as
Actin CytoskeletonActinsAdenosine TriphosphatasesAge of OnsetCardiomyopathy, HypertrophicFemaleHumansKineticsMaleMutation, MissenseMyocardial ContractionMyosin Light ChainsMyosinsSeverity of Illness IndexVentricular MyosinsActinsAdenosine Triphosphatasesmyosin light chain 3, humanMyosin Light ChainsMyosinsVentricular Myosinsactin-myosincardiomyopathyhypertrophic cardiomyopathykineticsmathematical modelingmolecular motorstructure-function
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.